New tablet and antibody combo for untreated follicular lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study tests a new drug combination (using two targeted medicines and an immunotherapy drug) versus a standard chemotherapy combination for people with untreated follicular lymphoma. The goal is to see if the new combo works better with fewer side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with follicular lymphoma (Grades 1, 2, or 3A).
- You have not yet had any treatment for your lymphoma.
- You are 18 years old or older.
- You are in fairly good health, able to do most daily activities (score 0–2 on a standard scale).
- Your blood counts, liver, and kidney function are within acceptable levels.
- You have a tissue sample (biopsy) available for testing, and you are willing to use effective birth control if you could become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs for people with previously untreated follicular lymphoma. The goal is to see if this combination helps control the lymphoma better.
This trial tests a combination of targeted therapy (zanubrutinib) and chemotherapy (G-CVP) for people with follicular lymphoma who have not had treatment before. It aims to see if this combination is safe and effective.
This trial tests a combination of two drugs, zuberitamab and bendamustine, for people with a type of lymphoma called follicular lymphoma who have not had treatment before. The goal is to see if this combination is safe and effective, and then if keeping on one of the drugs alone helps keep the cancer from coming back.
This study is testing a combination of three drugs—zanubrutinib, obinutuzumab, and lenalidomide—as a first treatment for people with a certain type of follicular lymphoma that is considered high-risk. The goal is to see if this combination is safe and effective in controlling the cancer.
This real-world study looks at how well obinutuzumab-based treatment works for people with newly diagnosed follicular lymphoma. It is meant for patients whose cancer is measurable on scans and who are eligible for specific standard treatment combinations.
This trial tests a combination of three drugs (orelabrutinib, tafasitamab, and lenalidomide) for people newly diagnosed with follicular lymphoma. The goal is to see if this combination can shrink or control the cancer and improve outcomes.
Hear when a new Follicular Lymphoma ( FL) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.